Patterns and predictors of relapse in Merkel cell carcinoma: Results from a population-based study

Joseph, Kurian; Wong, Jiemin; Abraham, Aswin George; Zebak, Julia; Patel, Anushree; Thachuthara, Aoife Jones; Iqbal, Umar; Pham, Truong-Minh; Menon, Anjali Kondur; Ghosh, Sunita; Warkentin, Heather; Walker, John; Jha, Naresh; Faruqi, Salman; Salopek, Thomas G.; Smylie, Michael

doi:10.1016/j.radonc.2021.11.015

Cited by 6 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of Merkel cell carcinoma is also significantly increased in patients with different types of immunosuppression including autoimmune diseases, neoplastic comorbidities, immunosuppression due to hemato-lymphoid disorders such as chronic lymphocytic leukemia/small lymphocytic lymphoma, and immune-modulating drugs or after solid organ transplantation. Moreover, immunosuppression significantly correlated with disease progression in these patients ( 34 – 37 ).…”

Section: Resultsmentioning

confidence: 91%

Hemato-Oncological Diseases as Risk Factor for Recurrence or Metastasis of Pleomorphic Dermal Sarcoma

Helbig

2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundAtypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) are increasingly common sarcomas of the skin with a genetic UV signature. Immunosuppression is a known risk factor for developing other UV-induced skin cancers such as cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC), and Merkel cell carcinoma with increased mortality. In case reports or small case series of AFX/PDS patients, immunosuppression has been hypothesized as a risk factor for the development of distant metastases. The aim of the present study was to analyze immunosuppression as a risk factor for AFX/PDS in a large patient cohort.MethodsA cohort of 164 patients with AFX/PDS (47 AFX and 117 PDS) was collected between 2003 and 2021 and analyzed for clinicopathological data with a special focus on immunosuppression.ResultsOf all patients, 29.9% had any kind of immunosuppression; 6.4% of the AFX and 12.0% of the PDS patients had underlying hemato-oncological diseases. Patients with immunosuppression due to an underlying hemato-oncological disease had a significantly increased risk of progressing to (p = 0.010) and developing distant organ metastases (p = 0.000).ConclusionsImmunosuppression seems to be a risk factor for developing AFX/PDS with worse clinical outcomes. Therefore, immunosuppression, especially underlying hemato-oncological diseases, should be considered in the treatment and follow-up care of patients with AFX/PDS.

show abstract

Section: Resultsmentioning

confidence: 91%

Hemato-Oncological Diseases as Risk Factor for Recurrence or Metastasis of Pleomorphic Dermal Sarcoma

Helbig

2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Of 618 MCC patients, the 5-year recurrence rate was 40%, and 95% of recurrences arose within the first 3 years (12). Beyond 3 years, the recurrence-free survival curves plateau among all stages of MCC, including older studies that predated use of anti-PD-1/PD-L1, as well as from data from our institution (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). The Yale Cancer Center MCC registry includes data from 216 MCC patients collected from 1996 to 2022.…”

Section: Discussionmentioning

confidence: 95%

Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases

et al. 2023

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is a rare tumor with a high risk of recurrence after definitive therapy; however, the optimal duration of surveillance is unclear. First recurrences typically occur within 3 years. National guidelines recommend that patients undergo physical examination and imaging for surveillance during this time period. However, the duration of surveillance beyond this is not defined. Here, we describe a case of a patient developing a recurrence of MCC 7 years after the primary diagnosis with interval in-transit and regional lymph node metastases 15 months following the treatment of the primary MCC. Such late recurrences are rare, largely not reported, and the risk factors contributing to late recurrences are not well described. This case highlights the possibility of late recurrences of MCC after an initial in-transit and nodal recurrence and underscores the importance of identifying predictors of recurrence that may better guide the duration of surveillance.

show abstract

Merkel Cell Carcinoma

Veness

2023

Radiotherapy in Skin Cancer

View full text Add to dashboard Cite

Patterns and predictors of relapse in Merkel cell carcinoma: Results from a population-based study

Cited by 6 publications

References 28 publications

Hemato-Oncological Diseases as Risk Factor for Recurrence or Metastasis of Pleomorphic Dermal Sarcoma

Hemato-Oncological Diseases as Risk Factor for Recurrence or Metastasis of Pleomorphic Dermal Sarcoma

Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases

Merkel Cell Carcinoma

Contact Info

Product

Resources

About